摘要
目的:观察黄芪胶囊对桥本氏甲状腺炎患者血清甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(Tg Ab)的影响。方法:60例确诊为桥本氏甲状腺炎患者随机分成治疗组30例和对照组30例;对照组仅予低碘饮食,治疗组在此基础上加黄芪胶囊治疗,疗程12周。观察TPOAb、Tg Ab、血清游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺素(TSH)的变化,评价疗效。结果:在降低TPOAb、Tg Ab水平方面,治疗组治疗前后比较均有统计学意义(P<0.01),对照组治疗前后比较均无统计学意义(P>0.05)。2组治疗前后TPOAb、Tg Ab的差值比较均有统计学意义(P<0.01)。且2组治疗前后TPOAb、Tg Ab下降的有效率比较均有统计学意义(P<0.01)。FT3、FT4、TSH2组治疗前后变化及差值均无统计学意义(P>0.05)。结论:黄芪胶囊能降低桥本氏甲状腺炎患者TPOAb、Tg Ab的水平,改善甲状腺自身免疫反应,临床疗效良好,无不良反应。
Objective： To observe the effect of Huangqi capsule on serum thyroid peroxidase antibody（ TPOAb） and thyroglobulin antibody（ Tg Ab） in patients with Hashimoto＇s thyroiditis. Methods： Sixty patients with Hasimoto＇s thyroiditis were randomly divided into treatment group（ 30 cases） and control group（ 30 cases）. The control group only received a low iodine diet,and the treatment group accept Huangqi capsule on the basis of low iodine. The duration of treatment was 12 weeks. The change of TPOAb,Tg Ab,serum free triiodothyronine（ FT3）,free thyroxine（ FT4） and thyroid stimulatting hormone（ TSH） were observed after treatment. Results： After treatment,the TPOAb and Tg Ab level were reduced significantly in treatment group（ P 〈0. 01）,but there is no difference in the control group. There was no significant difference in FT3,FT4 and TSH in both groups before and after treatment（ P〉 0. 05）. Conclusion： Huangqi capsule can reduce the TPOAb and Tg Ab levels of HT patients,and improve the thyroid autoimmune reaction with a favorable clinical effect,with no adverse reactions.
出处
《世界中医药》
CAS
2016年第7期1279-1281,1285,共4页
World Chinese Medicine
基金
上海市科学技术委员会科研计划项目(编号:13401903200)
上海市科学技术委员会科研计划项目(编号:14401930600)
